JOHN VIERLING to Nausea
This is a "connection" page, showing publications JOHN VIERLING has written about Nausea.
Connection Strength
0.054
-
Seladelpar (MBX-8025), a selective PPAR-d agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study. Lancet Gastroenterol Hepatol. 2017 10; 2(10):716-726.
Score: 0.033
-
Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection. Hepatology. 2010 Sep; 52(3):822-32.
Score: 0.021